NVAX

7.4703.24%
JC

John Charles Jacobs

President, CEO & Director

Mr. John Charles Jacobs, M.B.A., serves as Director at Ambros Therapeutics, Inc. since August 2026. He serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences Pennsylvania from May 06, 2021 until January 2023. He served as President, CEO and Director of Harmony Biosciences, LLC from March 2020. He serves as a Board Member of CiRC Biosciences. He was Chairman, President & CEO of Harmony Biosciences, LLC from 2019 to March 2020. He served as Chairman of Harmony Biosciences, LLC since 2019 until March 2020. He served as President, Chief Executive Officer of Harmony Biosciences Holdings, Inc. since June 2018 until January 06, 2023. Previously, Mr. Jacobs served as Executive Vice President and Chief Commercial Officer at Harmony Biosciences Holdings, Inc. from October 2018 to June 2018. He joined Harmony from Teva Pharmaceuticals Industries Ltd., where he held leadership roles as Senior Vice President and General Manager of the Respiratory Business Unit from September 2017 to October 2017, Senior Vice President of Commercial Operations in North America and General Manager of Teva in Canada. Mr. Jacobs has commercial experience across multiple therapeutic areas, including CNS, Sleep Disorders, Pain Care and Respiratory, as well as rare disease and other specialty markets. His demonstrated expertise in developing market-leading commercial strategies, major product launches and building and leading highly effective teams and organizations has helped to shape Harmony’s positive culture of compassion for patients and passion for the business. Mr. Jacobs served as Chief Commercial Officer and Executive Vice President of Harmony Biosciences, LLC. He joined Harmony from Teva Pharmaceuticals where he served as Senior Vice President and General Manager of the Respiratory BU, General Manager of Teva in Canada from September 2017 to October 2017. He was President and Chief Executive Officer and a member of the board of directors at Teva Pharmaceuticals Industries Ltd. from June 2018 to January 2023. Prior to joining Teva, he held leadership roles at a number of pharmaceutical companies including Cephalon and Wyeth. Mr. Jacobs has commercial experience including rare disease and specialty markets. He also served as Senior Vice President of Commercial Operations and Innovation of Teva, from September 2016 to September 2017 and as Vice President and General Manager of Teva Branded Business in Canada from July 2014 to September 2016. Mr. Jacobs holds a B.S. in business and a Master of Business Administration in marketing from the State University of New York and M.B.A. from the State University of New York at Binghamton.

Positions